Dendrite acquires Optas in $12 million deal

Share this article:
Pharma sales force effectiveness firm Dendrite announced that it has acquired relationship marketing firm Optas. The acquisition is valued at $12 million and will be funded by cash, Dendrite said in a statement.
Optas will be rebranded as "Optas: A Divison of Dendrite International."
A Dendrite spokeswoman told MM&M that no jobs will be eliminated as a result of the deal and key management posts on both sides of the deal will remain the same for the foreseeable future.
"Our combined offering will enable pharma companies to reach physicians and patients with consistent messaging and campaigns driven by deep patient and physician knowledge," said Stephen Smith, chief executive of Optas, in a statement.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union